Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals plc is a U.S.-based biopharmaceutical company focused on sleep-disorder therapies, with LUMRYZ as its only commercial product. LUMRYZ is an extended-release sodium oxybate formulation taken once at bedtime for cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company is also expanding its pipeline through a global license for valiloxybate, a GABAB receptor agonist being developed for sleep disorders including narcolepsy and idiopathic hypersomnia. Avadel’s business model is centered on specialty pharmaceutical commercialization, regulatory execution, and defending its products against competition and patent challenges.

−23,5 %

91,0 %

−28,9 %

+504,8 %

2.75

2.33

— Avadel Pharmaceuticals PLC
%
Commercial product100% LUMRYZ is the company’s marketed once-nightly sodium oxybate therapy for narcolepsy-related symptoms.
Pipeline development0% Valiloxybate and related sleep-disorder programs represent future product opportunities under license.
Licensing and commercialization rights0% The company acquires and develops rights to compounds and then seeks regulatory approval and market access.

Avadel sells primarily into the narcolepsy treatment market, where prescribing physicians choose therapies for patients...

  • Narcolepsy patientsprimary

    Patients with cataplexy or excessive daytime sleepiness who use LUMRYZ for symptom control and convenience.

  • Prescribing physiciansprimary

    Sleep specialists and neurologists who select oxybate therapy based on efficacy, dosing burden, and safety profile.

  • Payers and reimbursement bodiesprimary

    U.S. insurers and other third-party payers that influence access through formulary placement and coverage decisions.

  • Future sleep-disorder patientsemerging

    Potential patients with idiopathic hypersomnia or other sleep disorders targeted by the valiloxybate pipeline.

Avadel is headquartered in the United States and its commercial exposure is primarily tied to the U.S...

  • •United States is the core commercial market for LUMRYZ
  • •U.S. reimbursement policy directly affects patient access and pricing
  • •E.U. payer systems are referenced as a commercialization factor
  • •Non-U.S. subsidiary creates foreign currency translation exposure
  • •Global license for valiloxybate expands future geographic optionality

Avadel’s near-term strategy is to grow LUMRYZ adoption while managing competitive pressure from generic and...

01
Grow LUMRYZ adoptionshort-term

The company depends on one commercial product, so prescription growth is the main driver of revenue and operating leverage.

02
Defend market position against generic competitionshort-term

Generic and authorized-generic sodium oxybate products can pressure share, pricing, and physician switching behavior.

03
Advance valiloxybate developmentmedium-term

A second asset could reduce concentration risk and create a broader sleep-disorder franchise.

04
Maintain access to capital and liquidityshort-term

The company notes reliance on external capital and the need to fund commercialization and development activities.

Avadel faces concentrated product risk because LUMRYZ is its only commercial product, so any slowdown in uptake,...

high

Single-product concentration

LUMRYZ is the only commercial product, so revenue and profitability depend heavily on one asset.

Scope
Commercial revenue and operating income
Materiality
high
high

Generic competition

Generic and authorized-generic oxybate products can reduce pricing power and patient share.

Scope
LUMRYZ market share and gross profit
Materiality
high
high

Patent and IP litigation

Third-party claims can delay commercialization or expansion into new indications and create legal expense.

Scope
Regulatory timing and launch plans
Materiality
high
medium

Reimbursement and pricing pressure

Payer coverage and healthcare cost containment directly affect access and realized pricing.

Scope
U.S. commercialization economics
Materiality
high
medium

Capital access and dilution

The company states it may rely on external capital, which can be expensive or dilutive.

Scope
Liquidity and funding for commercialization
Materiality
medium
medium

Pending Alkermes transaction

Failure or delay in completing the transaction could adversely affect results and share price.

Scope
Corporate strategy and market valuation
Materiality
medium
Revenue recognition for product sales
Quarterly revenue and gross margin
Contingencies and litigation reserves
Operating expenses and liabilities
Foreign currency translation
Equity and other comprehensive income
Valuation of licensed development rights
Balance sheet carrying values and future amortization

Alkermes plc.

ALKS · Pharmaceutical Preparations

ADIAL PHARMACEUTICALS, INC.

ADIL · Pharmaceutical Preparations

Vanda Pharmaceuticals Inc.

VNDA · Pharmaceutical Preparations

Avalo Therapeutics, Inc.

AVTX · Pharmaceutical Preparations

Jazz Pharmaceuticals plc

JAZZ · Pharmaceutical Preparations

Harmony Biosciences Holdings, Inc.

HRMY · Pharmaceutical Preparations

: 11/08/2026